微流控芯片检测肺癌患者血浆中p16基因异常甲基化在临床应用的评价  

The Evaluation in Clinical Application of Detecting Aberrant Methylation of p16 Gene by Microfluidic Chips in Lung Cancer Patients

作　　者：汪洋[1] 邹丽娟[2] 许冠东[3] 宫琳琳[1] 周小棉[4] 邵淑娟[1] 

机构地区：[1]大连医科大学组织学与胚胎学教研室,大连116027 [2]大连医科大学附属第二医院肿瘤科,大连116027 [3]中国医学科学院肿瘤研究所病因研究室,北京100021 [4]中国科学院化学物理研究所,大连116025

出　　处：《生物化学与生物物理进展》2004年第12期1085-1090,共6页Progress In Biochemistry and Biophysics

基　　金：国家重点基础研究发展规划资助项目 ( 973 ) ( 2 0 0 2CB5 13 10 6);辽宁省教委科技资助项目 ( 2 0 2 2 0 3 2 48)~~

摘　　要：肺癌是常见的恶性肿瘤之一 ,其死亡率和发病率在世界范围的肿瘤性疾病中均居高不下 .p16基因启动子区异常甲基化被认为是肺癌发生中的一起早期事件 .为了提高检测异常甲基化方法的灵敏度及特异性 ,利用微流控芯片检测p16基因的异常甲基化 ,通过对肺癌患者血浆标本的检测 ,使病人血浆中的p16基因甲基化的异常改变可能成为辅助肺癌早期诊断和高危人群筛选的分子标记物 。Lung cancer is one of the malignant tumors. The death rate and incidence are very high through the whole world. Aberrant methylation of p16 gene promoter is thought to be an early event in lung cancer development. To improve the sensitivity and specificity, the microfluidic chip method was established to detect the aberrant methylation of p16 gene. The plasma samples of lung cancer patients were detected. The p16 gene methylation can perhaps become a biomarker for early lung cancer. It may become a new and reliable method for early diagnosis of lung cancer.

关 键 词：p16基因 甲基化 微流控芯片 甲基化特异性PCR 

分 类 号：R730[医药卫生—肿瘤]